Takeda
Japan's largest pharmaceutical company, partnering with AI-native discovery companies across small molecules and protein therapeutics.
- Company type
- Global pharmaceutical company
- Headquarters
- Tokyo, Japan
- Website
- https://www.takeda.com
- Profile last verified
- 2026-07-29
AI Partnerships & Deployments
- 2026-07-01 — Strategic AI drug discovery collaboration with Insilico Medicine (Insilico Medicine). Multi-program collaboration applying Insilico's Pharma.AI platform to identify drug candidates with potential for clinical differentiation across Takeda's core therapeutic areas. Nikkei Asia reported the deal is worth up to $600 million including milestones. Disclosed: Up to $600M including milestones (per Nikkei Asia). Source: PR Newswire (Insilico Medicine release) (accessed 2026-07-29)
- 2025-10-14 — Second AI protein-design collaboration with Nabla Bio (Nabla Bio). Expanded partnership using Nabla Bio's JAM generative AI platform for de novo design of protein therapeutics, following an earlier Takeda–Nabla collaboration. Financial terms were not disclosed. Source: Business Wire (Nabla Bio release) (accessed 2026-07-29)